Yoram Shechter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yoram Shechter has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Haim Tsubery
Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel
4 shared publications- Mati Fridkin
Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel
4 shared publications K. Sasson
Department of Biological-Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel
3 shared publicationsM. Mironchik
Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel
3 shared publicationsMati Fridkin
Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel
3 shared publicationsS. Rubinraut
Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel
3 shared publications
Latest Publications
- 16 February 2010
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 1 (5) , 399-406
Delivery of Neuropeptides from the Periphery to the Brain: Studies with Enkephalin
Many peptides with the potential of therapeutic action for brain disorders are not in clinical use because they are unable to cross the blood−brain barrier (BBB) following peripheral administration. We have developed two potential strategies for the delivery of peptides to the brain and demonstrated their feasibility with enkephalins. In the first approach, designated induced reversible lipophilization, Leu/Met Enkephalins were converted to 9-fluorenylmethoxycarbonyl (Fmoc) derived lipophilic prodrug analogues, which undergo slow, spontaneous hydrolysis under physiological conditions, generating the native agonists. In contrast to Enkephalin, Fmoc-Met-Enkephalin was found to facilitate an analgesic effect following intraperitoneal administration in mice. Fmoc-Leu-Enkephalin was not analgesic. In the second approach, Enkephalin was linked to BBB transport vectors through an Fmoc based linker spacer, forming conjugates that slowly release Enkephalin under physiological conditions. A pronounced antinociceptive response was thus obtained following intraperitoneal administration of either cationized-human serum albumin-Fmoc-Enkephalin or polyethylene glycol5-Fmoc-Enkephalin. Derivatives of Enkephalin covalently linked to the same BBB-transport vectors through a stable (nonreversible) chemical bond were not analgesic. In summary, we have demonstrated that lipophilicity can be conferred to hydrophilic peptides to a degree permitting the permeation of the BBB by passive diffusion, without the drawback of agonist inactivation, which is often caused by irreversible derivatization. Similarly, in the second strategy, the conjugation to BBB-permeable vectors overcomes the obstacle of peptide inactivation by releasing the active form in the central nervous system.
- 16 February 2010
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 1 (5) , 399-406
Delivery of Neuropeptides from the Periphery to the Brain: Studies with Enkephalin
Many peptides with the potential of therapeutic action for brain disorders are not in clinical use because they are unable to cross the blood−brain barrier (BBB) following peripheral administration. We have developed two potential strategies for the delivery of peptides to the brain and demonstrated their feasibility with enkephalins. In the first approach, designated induced reversible lipophilization, Leu/Met Enkephalins were converted to 9-fluorenylmethoxycarbonyl (Fmoc) derived lipophilic prodrug analogues, which undergo slow, spontaneous hydrolysis under physiological conditions, generating the native agonists. In contrast to Enkephalin, Fmoc-Met-Enkephalin was found to facilitate an analgesic effect following intraperitoneal administration in mice. Fmoc-Leu-Enkephalin was not analgesic. In the second approach, Enkephalin was linked to BBB transport vectors through an Fmoc based linker spacer, forming conjugates that slowly release Enkephalin under physiological conditions. A pronounced antinociceptive response was thus obtained following intraperitoneal administration of either cationized-human serum albumin-Fmoc-Enkephalin or polyethylene glycol5-Fmoc-Enkephalin. Derivatives of Enkephalin covalently linked to the same BBB-transport vectors through a stable (nonreversible) chemical bond were not analgesic. In summary, we have demonstrated that lipophilicity can be conferred to hydrophilic peptides to a degree permitting the permeation of the BBB by passive diffusion, without the drawback of agonist inactivation, which is often caused by irreversible derivatization. Similarly, in the second strategy, the conjugation to BBB-permeable vectors overcomes the obstacle of peptide inactivation by releasing the active form in the central nervous system.
- 30 October 2009
- Published by Elsevier in Journal of Controlled Release
- Vol. 142 (2) , 214-220
Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions
- 30 October 2009
- Published by Elsevier in Journal of Controlled Release
- Vol. 142 (2) , 214-220
Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions
- 7 April 2008
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 70 (1) , 19-28
Reversible pegylation of insulin facilitates its prolonged action in vivo
- 7 April 2008
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 70 (1) , 19-28
Reversible pegylation of insulin facilitates its prolonged action in vivo
- 12 December 2006
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 13 (1-2) , 105-117
New Technologies to Prolong Life-time of Peptide and Protein Drugs In vivo
- 12 December 2006
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 13 (1-2) , 105-117
New Technologies to Prolong Life-time of Peptide and Protein Drugs In vivo
- 1 July 2005
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 16 (4) , 913-920
Albumin−Insulin Conjugate Releasing Insulin Slowly under Physiological Conditions: A New Concept for Long-Acting Insulin
The covalent linkage of peptides or protein drugs to human serum albumin (HSA) greatly prolongs their lifetime in vivo but is pharmacologically irrelevant when it irreversibly inactivates them. We retain drug bioactivity by synthesizing a heterobifunctional reagent (MAL-Fmoc-OSu, 9-hydroxymethyl-2-(amino-3-maleimidopropionate)-fluorene-N-hydroxysuccinimide) that generates HSA−Fmoc−insulin on covalent conjugation to the amino group of insulin and the Cys-34 side chain of HSA. HSA−Fmoc−insulin is water-soluble and, upon incubation in aqueous buffers reflecting normal human serum conditions, slowly, spontaneously, and homogeneously hydrolyzes to release unmodified insulin with a t1/2 of 25 ± 2 h. A single subcutaneous or intraperitoneal administration of HSA−Fmoc−insulin to diabetic rodents lowers circulating glucose levels for about 4 times longer than an equipotent dose of Zn2+-free insulin. Following subcutaneous administration, onset of the glucose-lowering effect is delayed 0.5−1 h and persists for 12 h. Thus, we present a prototype insulin formulation possessing three desirable parameters: high aqueous solubility, delayed action following subcutaneous administration, and prolonged therapeutic effect.
- 1 July 2005
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 16 (4) , 913-920
Albumin−Insulin Conjugate Releasing Insulin Slowly under Physiological Conditions: A New Concept for Long-Acting Insulin
The covalent linkage of peptides or protein drugs to human serum albumin (HSA) greatly prolongs their lifetime in vivo but is pharmacologically irrelevant when it irreversibly inactivates them. We retain drug bioactivity by synthesizing a heterobifunctional reagent (MAL-Fmoc-OSu, 9-hydroxymethyl-2-(amino-3-maleimidopropionate)-fluorene-N-hydroxysuccinimide) that generates HSA−Fmoc−insulin on covalent conjugation to the amino group of insulin and the Cys-34 side chain of HSA. HSA−Fmoc−insulin is water-soluble and, upon incubation in aqueous buffers reflecting normal human serum conditions, slowly, spontaneously, and homogeneously hydrolyzes to release unmodified insulin with a t1/2 of 25 ± 2 h. A single subcutaneous or intraperitoneal administration of HSA−Fmoc−insulin to diabetic rodents lowers circulating glucose levels for about 4 times longer than an equipotent dose of Zn2+-free insulin. Following subcutaneous administration, onset of the glucose-lowering effect is delayed 0.5−1 h and persists for 12 h. Thus, we present a prototype insulin formulation possessing three desirable parameters: high aqueous solubility, delayed action following subcutaneous administration, and prolonged therapeutic effect.
- 27 June 2003
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 307 (2) , 315-321
Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats
- 27 June 2003
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 307 (2) , 315-321
Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats
- 15 August 2002
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (19) , 4264-4270
N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl]3-gentamicin C1 Is a Long-Acting Prodrug Derivative
Most low-molecular-weight drugs are short-lived species in the circulatory system, being rapidly eliminated by glomerular filtration in the kidney. However, binding to human serum albumin (HSA) can slow clearance and prolong lifetime profile in vivo. In this study, we have engineered a gentamicin derivative with affinity to albumin by linking three (2-sulfo)-9-fluorenylmethoxycarbonyl (FMS) to three amino groups of gentamicin C1. FMS3-gentamicin associates with HSA with a Ka value of (1.31 ± 0.2) × 105 M-1. It has less than 1% the antibacterial potency of native gentamicin. Upon incubation at pH 8.5 and 37 °C, the FMS moieties from FMS3-gentamicin undergo slow hydrolysis (t1/2 = 8.0 ± 0.2 h), leading to a linear regeneration of the antibacterial potency with a t1/2 value of 11 ± 0.7 h. FMS3-gentamicin is a long-lived species in the rat circulatory system. Following a single subcutaneous or intravenous administration, it maintains a prolonged pharmacokinetic profile with a peak and a “through” concentration of immuno/antibacterial active gentamicin exceeding 4−5 times the duration obtained by administered native gentamicin. To sum up, an approach aimed at elongating the lifetime of low-molecular-weight drugs in vivo has been examined here with gentamicin. Two to three FMS per mole of compound are to be introduced to obtain an albumin associating affinity of Kd = 7.6−9.2 μM and, hence, to significantly extend the drug's lifetime in situ following administration. By use of this technology, the loss of pharmacological potency with derivatization is of no consequence, since FMS moieties are hydrolyzed and activity is generated at physiological conditions.
- 15 August 2002
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (19) , 4264-4270
N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl]3-gentamicin C1 Is a Long-Acting Prodrug Derivative
Most low-molecular-weight drugs are short-lived species in the circulatory system, being rapidly eliminated by glomerular filtration in the kidney. However, binding to human serum albumin (HSA) can slow clearance and prolong lifetime profile in vivo. In this study, we have engineered a gentamicin derivative with affinity to albumin by linking three (2-sulfo)-9-fluorenylmethoxycarbonyl (FMS) to three amino groups of gentamicin C1. FMS3-gentamicin associates with HSA with a Ka value of (1.31 ± 0.2) × 105 M-1. It has less than 1% the antibacterial potency of native gentamicin. Upon incubation at pH 8.5 and 37 °C, the FMS moieties from FMS3-gentamicin undergo slow hydrolysis (t1/2 = 8.0 ± 0.2 h), leading to a linear regeneration of the antibacterial potency with a t1/2 value of 11 ± 0.7 h. FMS3-gentamicin is a long-lived species in the rat circulatory system. Following a single subcutaneous or intravenous administration, it maintains a prolonged pharmacokinetic profile with a peak and a “through” concentration of immuno/antibacterial active gentamicin exceeding 4−5 times the duration obtained by administered native gentamicin. To sum up, an approach aimed at elongating the lifetime of low-molecular-weight drugs in vivo has been examined here with gentamicin. Two to three FMS per mole of compound are to be introduced to obtain an albumin associating affinity of Kd = 7.6−9.2 μM and, hence, to significantly extend the drug's lifetime in situ following administration. By use of this technology, the loss of pharmacological potency with derivatization is of no consequence, since FMS moieties are hydrolyzed and activity is generated at physiological conditions.
- 1 January 2001
- Published by Portico in Drugs of the Future
- Vol. 26 (7) , 0669
A new approach for prolonging the half-life of peptides, proteins and low-molecular-weight drugs in vivo
- 1 January 2001
- Published by Portico in Drugs of the Future
- Vol. 26 (7) , 0669
A new approach for prolonging the half-life of peptides, proteins and low-molecular-weight drugs in vivo